Status:
COMPLETED
"L-Sandwich" Strategy in the True Coronary Bifurcation Lesions
Lead Sponsor:
Henan Institute of Cardiovascular Epidemiology
Conditions:
Coronary Disease
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
The treatment of coronary bifurcation lesions continue to remain challenges. Due to the complexity of the anatomical structure and the limitations of imaging, there are poor attachment and under-expan...
Detailed Description
This is a study to evaluate the application of L-Sandwich in true bifurcation coronary artery disease.All eligible patients were randomly divided into three groups: experimental group 1: dual stent gr...
Eligibility Criteria
Inclusion
- Patients with true bifurcation disease with SB lesion length\>25mm
Exclusion
- SB diameter\<2.5mm
- presence of cardiogenic shock or cardiopulmonary resuscitation
- Expected survival \<1 year
- Allergy to indexed medications
- Intolerable to dual antiplatelet therapy
- pregnant
- Severe calcification needing rotational atherectomy
Key Trial Info
Start Date :
October 3 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 20 2022
Estimated Enrollment :
107 Patients enrolled
Trial Details
Trial ID
NCT04753827
Start Date
October 3 2021
End Date
July 20 2022
Last Update
August 5 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fuwai central China cardiovascular Hospital
Zhengzhou, Henan, China